ENCODING SCAR-LESS HEALING
Targeting Unmet Needs in COVID-19,
Aesthetic Surgery & Burn Care
CELLASTRA GENE THERAPY REPORT JANUARY 12, 2021
CELLASTRA INC. 12/23/2020
Cellastra announces the appointment of Professor Sarah Wootton, PhD, as Member of Cellastra’s Scientific Advisory Board
San Francisco, CA, December 23, 2020, Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today, that the company has appointed Professor Sarah Wootton, PhD, as new Member of Cellastra’s Scientific Advisory Board.
CELLASTRA INC. 08/07/2020
Cellastra announces the appointment of BIOTECanada veteran Brad Thompson, PhD, as Chairman of the Board and Ex Novartis veteran Vinod Kumar, MD, as Chief Medical Officer.
CELLASTRA INC 03/03/2020
Cellastra announces long-term results from in-vivo transgene expression of proprietary anti-scarring peptide
PrSan Francisco, CA, March 3, 2020 Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.
Cellastra recently reported results demonstrating that CELLEXA delivers the genetic code for the lactoferrin sub-peptide with the same amino acid sequence enabling expression during the first month of ovservation.
“Our new results from long-term follow up demonstrates continued robust and durable transgenic expression and production of the peptide throughout the 11 week observation period after intramuscular injection, and furthermore no adverse effects were noted” said Dr Karl Mettinger, MD, PhD, President & CEO of C
NEW GENE THERAPY INSTITUTE CREATE BY NIH